Profil
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd.
from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd.
in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd.
Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Anciens postes connus de Michal Ayalon
| Sociétés | Poste | Fin |
|---|---|---|
| KAMADA LTD. | Directeur Technique/Scientifique/R&D | 28/02/2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Directeur Technique/Scientifique/R&D | 01/01/2019 |
| GALMED PHARMACEUTICALS LTD. | Directeur Technique/Scientifique/R&D | 01/01/2016 |
Formation de Michal Ayalon
| Tel-Aviv University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALMED PHARMACEUTICALS LTD. | Health Technology |
| KAMADA LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |
